Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab

EP: 1.How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?

EP: 2.Overview of Relapsed/Refractory Multiple Myeloma

EP: 3.MonumenTAL-1: Talquetamab in Relapsed/Refractory MM

EP: 4.Talquetamab Safety Profile in Relapsed/Refractory MM

Now Viewing

EP: 5.Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab

EP: 6.GPRC5D-Related Oral Adverse Events in Multiple Myeloma

EP: 7.MonumenTAL-1: Proactive Management of Oral Toxicities

EP: 8.Multiple Myeloma: Educating Patients on Oral Toxicity Management

EP: 9.Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma

EP: 10.Conclusions from MonumenTAL-1 Study in Multiple Myeloma

This is a video synopsis/summary of a Between the Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.

For cytokine release syndrome (CRS) management with tocilizumab, Mount Sinai Health System in New York, New York, employs early intervention with tocilizumab at initial fever onset, avoiding corticosteroids initially. Memorial Sloan Kettering Cancer Center in New York, New York, also uses early tocilizumab trigger at first fever, having overcome hesitancy from chimeric antigen receptor T-cell therapy experience given lack of efficacy impact.

Regarding infection prophylaxis with talquetamab, varicella-zoster virus and Pneumocystis jirovecii pneumonia prophylaxis are used, with little other antimicrobial prophylaxis unless prior infection directs tailored approaches. Some differences persist in GPRC5D infectious risk precaution vs BCMA regimens.

Video synopsis is AI generated and reviewed by CancerNetwork® editorial staff.